Laserfiche WebLink
State of California and Welfare Agency <br />gra r., <br />Departimrrt of Health Services <br />Page of •.r- <br />.- r- <br />• - ,w- <br />6. Nuclide <br />7. Form <br />8. Possession Limit <br />E. Group 6 as specified in <br />E. <br />E. <br />Item 9. <br />1. Cesium 137 <br />1. Sealed sources <br />1. Total 300 mCi, in 6 <br />sources, no single <br />source to exceed 75 <br />MG. <br />2. Radium 226 <br />2. Sealed sources <br />2. Total 100 mg, in 6 <br />sources, no single <br />source to exceed 25 <br />Mg. <br />3. Iodine 125 <br />3. Seeds <br />3. 100 mCi <br />4. Palladium 103 <br />4. Seeds <br />4. 500 mCi <br />5. Strontium 90 <br />5. Applicator <br />5. Total 50 mCi, in 1 <br />source, no single= <br />source to exceed 50 <br />mCi. <br />F. Group 9 as specified in <br />F. Sealed or solid sources <br />F. Total not to exceed 25 mCi. <br />Item 9. <br />manufactured in accordance <br />Each radionuclide not to <br />Any radionuclide with <br />with a specific license <br />exceed 15 mCi. <br />atomic number 3-83 <br />issued by the United States <br />inclusive, except: <br />Nuclear Regulatory <br />Strontium 90 and <br />Commission or an <br />Lead 210 <br />Agreement State. <br />9. Authorized Use <br />To be used for nuclear medicine procedures as specified in groups below. <br />A. Group 1 Diagnostic studies involving measurement of uptake, dilution, or excretion but not <br />involving imaging. <br />B. Group 2 Diagnostic studies involving imaging including the use of Xenon 127 and/or Xenon 133 <br />tom• <br />C. Group 3 Reagent kits utilizing bulk technetium prepared by a radiopharmacy for preparation of <br />radiopharmaceuticals listed in Group 2. <br />D. Group 4 Internal therapy not usually requiring hospitalization. <br />